Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTNK-tPA Dose Escalation for ICH
NCT06668441Phase 1Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenecteplase in intracerebral hemorrhage (ICH) (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Drug-related rebleeding events at 24 hours. Started Nov 2024; status: completed.
02
Drugs
tenecteplase
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT06668441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668441.